Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Stopped early · Phase 1/Phase 2

Conditions studied: Progressive Multifocal Leukoencephalopathy

In brief

The primary objective of the study was to explore whether mefloquine can delay or stop progression of progressive multifocal leukoencephalopathy (PML) as measured by JC virus (human polyomavirus or JCV) deoxyribonucleic acid (DNA) levels in cerebrospinal fluid (CSF). The secondary objective of the study was to explore whether mefloquine can delay or stop progression of PML based on neurological deterioration, magnetic resonance imaging (MRI) measures of brain lesion evolution or the formation of new lesions, and mortality.

Key facts

Study ID

NCT00746941

Run by

Biogen

People needed

37

Starts

2009-01-01

Expected to finish

2010-11-01

Last updated by the study team

2014-07-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Chicago, Illinois, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — St Louis, Missouri, United States
• Research Site — New York, New York, United States
• Research Site — São Paulo, Brazil
• Research Site — Düsseldorf, North Rhine-Westphalia, Germany
• Research Site — Berlin, Germany
• Research Site — Hamburg, Germany
• Research Site — Milan, Italy
• Research Site — Barcelona, Spain
• Research Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.